AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$206.68
−0.80%Sep 1, 2026, 17:05 UTC
Axsome Therapeutics began dosing in the Phase III SUMMIT study of AXS-05 for smoking cessation in adults.
Source:Aug 23, 2026, 08:03 UTC
BlackRock Inc. acquired a new minority stake in Axsome Therapeutics, Inc., buying 3,103,708 shares valued at approximately $759.70 million during the second quarter, as disclosed in its 13F filing with the SEC.
Source:Aug 10, 2026, 11:00 UTC
Axsome Therapeutics initiated FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD.
Source:Aug 10, 2026, 11:00 UTC
Axsome Therapeutics reported second quarter 2026 financial results with total net product revenue of $218.4 million, a 46% year-over-year increase.
Aug 10, 2026, 08:54 UTC
Axsome Therapeutics CEO Herriot Tabuteau sold 4,660 shares of the company's stock on August 6, 2026, at an average price of $213.95, totaling $997,007.
Source:Jul 16, 2026, 17:01 UTC
The FDA accepted Axsome Therapeutics' New Drug Application for AXS-12 for the treatment of cataplexy in narcolepsy and set a decision date of May 2027.
Source:Jul 7, 2026, 11:00 UTC
Axsome Therapeutics dosed the first patient in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD.
Source:Jun 6, 2026, 04:02 UTC
Axsome Therapeutics is preparing to launch Auvelity for Alzheimer's disease agitation this month.
Source:Jun 3, 2026, 11:00 UTC
Axsome Therapeutics resolved all patent litigation related to its product SUNOSI (solriamfetol).
Source: